UCB stock eases as Belgium shares hold near 52-week range
Published on 08/29/2026 at 15:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UCB stock (BE0003739530) fell 2.43% to EUR 216.50 in Brussels on August 28, 2026, leaving the Belgian drugmaker inside a EUR 51.47 billion market-cap frame reported this year. The latest reported half-year figures showed revenue of EUR 2.49 billion for the first six months of 2026 and core profit of EUR 760 million.
Half-year numbers
The first-half 2026 revenue figure rose from EUR 2.28 billion a year earlier, a gain of EUR 210 million, while core profit expanded from EUR 692 million in the same period of 2025. That keeps the comparison straightforward for investors: sales advanced 9.2%, and operating leverage was still visible at the profit line.
Those numbers matter because they show how UCB entered the late-summer trading window with a larger revenue base and a stronger underlying earnings line than a year earlier. The share price on August 28, 2026 also sat well below the reported 52-week high of EUR 237.80, leaving room for the market to keep focusing on execution rather than a single session move.
Market position
On the same market snapshot, UCB traded with a 52-week range of EUR 140.20 to EUR 237.80 and a market capitalization of EUR 51.47 billion as of February 25, 2026. The combination of a higher half-year revenue base and a share price still below the top of that range gives the stock a clear valuation backdrop into the next reporting period.
Belgian market coverage also showed UCB among the session's weaker large-cap names, with a 2.43% decline after the close on August 28, 2026. That move is more useful as a trading reference than as a fundamental verdict, because the core story is still anchored in the EUR 2.49 billion first-half sales line and the EUR 760 million core profit result.
Product focus
One of UCB's best-known products is the company's product pipeline, which covers marketed medicines and later-stage assets across neurology and immunology. For investors, that pipeline mix matters because UCB's half-year numbers point to a business that is still scaling while funding development.
Price and trading view
UCB stock traded at EUR 216.50 in Brussels on August 28, 2026, after a 2.43% drop in that session. The share price sits below the EUR 237.80 52-week high and above the EUR 140.20 low, keeping the stock in the middle of its yearly trading band.
Company
Company: UCB SA
ISIN: BE0003739530
Ticker: UCB
Exchange: Euronext Brussels
Price (as of August 28, 2026, 5:30 p.m. local time): EUR 216.50
Market cap: EUR 51.47 billion (as of February 25, 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: BEL 20
